GlassScriptPhysician profile
Simer Preet Singh
NPI 1942443452
$5,312.28
in general payments reported to CMS, 2019-2025
24 companies · $406 in 2025
The $406 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,207 · 2020: $11.28 · 2021: $53.26 · 2022: $960 · 2023: $379 · 2024: $295 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,080.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,359.82 | 2019-2025 | Proclaim, Eterna |
| Vertos Medical, INC. | $1,054.31 | 2019 | |
| Bioventus LLC | $740.89 | 2022 | |
| Medtronic, INC. | $513.24 | 2022-2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Nalu Medical, INC. | $140.80 | 2023 | Nalu Neurostimulation System |
| Boston Scientific Corporation | $83.57 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Braeburn INC. | $54.02 | 2025 | Brixadi |
| Scilex Pharmaceuticals INC. | $43.31 | 2019 | |
| Novartis Pharmaceuticals Corporation | $36.21 | 2019 | |
| Medtronic USA, INC. | $29.51 | 2019 | |
| Pfizer INC. | $27.54 | 2019 | |
| Tonix Medicines, INC. | $26.71 | 2025 | Tonmya |
| Alkermes, INC. | $26.00 | 2019 | |
| Ucb, INC. | $22.83 | 2024 | Fintepla |
| Averitas Pharma INC. | $21.96 | 2025 | Qutenza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $19.44 | 2025 | Xeomin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.77 | 2019 | |
| Collegium Pharmaceutical, INC. | $16.65 | 2025 | Belbuca |
| Saluda Medical Americas, INC. | $16.42 | 2024 | Evoke |
| Daiichi Sankyo INC. | $14.90 | 2019 | |
| Amgen INC. | $13.75 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.49 | 2019 | |
| Fidia Pharma USA INC. | $11.28 | 2020 | |
| Spr Therapeutics, INC | $9.86 | 2025 | Sprint Pns System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simer Preet Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.